

Support of Joint Function, Range of Motion, and Physical Activity Levels by Consumption of a Water-Soluble Egg Membrane Hydrolyzate

Gitte S. Jensen, Miki R. Lenninger, Joni L. Beaman, Robert Taylor, and Kathleen F. Benson

NIS Labs, Klamath Falls, Oregon.

ABSTRACT This study evaluated the effects of consumption of hydrolyzed water-soluble egg membrane (WSEM) on joint function in an otherwise healthy population experiencing chronic pain. A randomized, double-blind, placebo-controlled crossover study included two 4-week periods of placebo and WSEM consumption, separated by a 4-week washout period. Twenty-five study participants were randomized to either the “placebo-first” or “WSEM first” sequence in the crossover trial, and 22 participants completed the study requirements. Range of motion (ROM) was assessed using digital inclinometry for joints associated with vertical weight bearing from neck to knees and for shoulders. Pain at rest and when physically active was scored for the same anatomical areas using visual analog scales (VAS). Physical functioning was tracked using questionnaires with VAS. Consumption of WSEM was associated with improved ROM for neck, spine, hips, and knees, with ROM for the neck and right knee being significantly improved during WSEM consumption compared to placebo ($P < .05$). ROM improvement for the dominant shoulder was highly significant during WSEM consumption ($P < .01$). Physical activity levels were significantly higher after WSEM than after placebo consumption ($P < .05$). Many aspects of physical functioning as part of daily living improved. Subgroup analysis showed rapid improvement of lower back pain after 5 days of WSEM consumption compared to placebo consumption ($P < .05$) in subjects who participated in the study during the winter season. Daily consumption of 450 mg WSEM was associated with improved joint function, comfort during daily activities, and increased physical activity.

KEY WORDS: • *activities of daily living* • *back pain*

INTRODUCTION

AVIAN EGGSHELLS AND MEMBRANES are commonly disposed of as waste material by the liquid egg industry; however, the high content of bioactive components found within the egg membrane (EM) has received increasing attention. The natural biological role of EM is to act as a scaffold for the formation of the eggshell during development as well as to provide antimicrobial protection for the growing avian embryo.^{1–2} Chicken EM has especially received technological attention in the continued pursuit of improved biological and biodegradable matrices for regeneration in wounds,^{3–4} nerves,⁵ and joints/cartilage. EM has been found to display properties, including moisture retention and biodegradability, as well as aid in microencapsulation for nutrient delivery.⁶ Proteoglycans in EM have been successful in treating nonhealing wounds and burns due to their biocompatibility, biodegradability, and similarity to macromolecules found in the human body.⁷

Components and actions of chicken EM have been researched for decades for numerous industrial applications. Recent research has focused on its ability to perform as an extracellular matrix environment, nerve guide channels in peripheral nerve regeneration,⁵ nutrient delivery systems,⁶ and other biotechnical uses. However, the mechanisms by which EM supports tissue repairs have not yet been determined. Further evaluation is needed to determine EM's ability to support specific regenerative processes, in comparison with known factors that promote regeneration. Currently, the literature on EM falls into at least three categories based on the type of EM: crude/native, enzymatically digested, or hydrolyzed water-soluble material. It is important to scrutinize which material is used when evaluating data.

An EM-based dietary supplement containing glycosaminoglycans and essential proteins was found to be a successful treatment for pain and inflexibility caused by joint and connective tissue disorders in several clinical studies. In an initial open-label clinical study, supplementation with crude EM significantly increased flexibility in 7 days and significantly reduced general- and range of motion (ROM)-associated pain in 30 days.⁸ Crude EM has also been

Manuscript received 15 March 2015. Revision accepted 4 August 2015.

Address correspondence to: Gitte S. Jensen, PhD, NIS Labs, 1437 Esplanade, Klamath Falls, OR 97601, E-mail: gitte@nislabs.com

© Gitte S. Jensen et al. 2015; Published by Mary Ann Liebert, Inc. This Open Access article is distributed under the terms of the Creative Commons Attribution Noncommercial License (<http://creativecommons.org/licenses/by-nc/4.0/>) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

evaluated as a treatment option for osteoarthritis and was shown to significantly reduce joint pain and stiffness associated with knee osteoarthritis compared to placebo.⁹ As osteoarthritis requires long-term treatment, the use of EM offers a potentially beneficial complementary intervention, as it does not result in the side effects associated with analgesics and nonsteroidal inflammatory drugs.

More recently, EM was suggested to be safe for human consumption as it did not exhibit cytotoxic, genotoxic, acute, or repeated-dose oral toxicity in a preliminary study.¹⁰ In addition, EM has been documented to suppress production of proinflammatory cytokine production using an *in vitro* cellular model, suggesting future anti-inflammatory applications.¹¹ Of further interest, EM subjected to *in vitro* digestion was more effective in reducing production of the proinflammatory cytokine Tumor Necrosis Factor-Alpha than native EM when the cells were exposed to a mitogen. This provides support for the use of EM as a consumable anti-inflammatory supplement for the treatment of arthritic conditions.

The ability of hydrolyzed water-soluble EM (WSEM) to function as a surface for human dermal fibroblast adhesion *in vitro* was tested and showed that dermal fibroblasts adhered to a water-soluble alkaline-digested form of eggshell membrane conjugated to an artificial cell membrane biointerface.¹² As this scaffold has potential topical applications in wound healing, as well as deep-tissue applications such as stabilizing connective tissues, further study of WSEM was needed.

The controversy regarding whether orally delivered EM aids in regulating reparative mechanisms prompted the need for clinical documentation of effects associated with consumption of EM. Specifically, the documentation after consuming a WSEM hydrolyzate is an important step, due to the ease of delivery in multiple application systems associated with improving joint and connective tissue health. The effects of consuming WSEM were evaluated in a study population with osteoarthritis and showed significant reduction of C-reactive protein (CRP), as well as improved daily functioning (manuscript in preparation).

The clinical study reported here was conducted in a healthier study population and aimed at documenting whether consumption of hydrolyzed WSEM had clinically significant effects in relieving chronic pain associated with mild to moderate limitations to physical functioning. The study design aimed at collecting data on rapid effects as well as long-term observations.

MATERIALS AND METHODS

Study design

A randomized, double-blind, placebo-controlled crossover study design was used for this clinical study. Twenty-five people went through screening and were enrolled in the 12-week study upon signing written informed consent, as approved by the Sky Lakes Institutional Review Board before the study started (Table 1). Exclusion criteria included the following: previous major gastrointestinal surgery, intensive athletic training; major trauma or surgery in the past 6 months; use of injectable corticosteroids or other injectable pain pre-

TABLE 1. DEMOGRAPHICS OF STUDY PARTICIPANTS IN THE CROSSOVER STUDY

	WSEM first, placebo second	Placebo first, WSEM second	P
Females	8	7	
Age average ^a	54.3 ± 10.7	51.6 ± 9.6	.6102
Age range	37.7–73.5	36.1–67.9	
BMI average ^a	29.1 ± 3.7	27.2 ± 5.2	.4411
BMI range	23.4–34.6	20.8–34.5	
Males	5	5	
Age average ^a	49.5 ± 9.4	47.0 ± 8.1	.6577
Age range	38.4–58.4	37.1–58.9	
BMI average ^a	31.5 ± 2.8	30.3 ± 2.7	.4922
BMI range	28.7–34.9	27.0–34.4	

^aAverage ± standard deviation is shown.

BMI, body mass index; WSEM, water-soluble egg membrane.

scription medication within 6 months before randomization; use of prescription pain medications; daily consumption of over-the-counter pain medication; regular consumption of glucosamine, chondroitin, or hyaluronic acid; regular use of marijuana; active autoimmune disease; thyroid disease, inflammatory bowel disease or other active uncontrolled disease; diagnosis with fibromyalgia or chronic fatigue syndrome; severe degenerative musculoskeletal disease; cancer and/or chemotherapy during the last year; chronic viral infections; ongoing acute infections; currently experiencing asthma or taking asthma medications; frequent headaches, including migraines; currently taking antidepressant, antipsychotic, antianxiety and/or hypnotic medications; and currently on anti-inflammatory nutritional supplements judged by the study coordinator to negate or camouflage the effects of the test product.

Subjects were asked to maintain a constant intake of supplements over the time of the study. As documented by prescreening interviews, all study participants were on a normal diet (regular meals, no excessive consumption of sugar, soft drinks, or alcohol) and moderately active either by physical work or normal daily activities such as housework and gardening (no extreme athletes). Study participants were instructed to maintain their normal diet and lifestyle throughout the study. After a successful screening process, the participants were randomized to receive either product or placebo for the first 4-week phase of the crossover study. After the 4-week visit, they had a 4-week washout period, followed by a 4-week period of consuming the other test product. One set of study participants enrolled in November 2013 and completed the study in February 2014. Another set enrolled in January 2014 and completed the study in April 2014. The study was carried out in Southern Oregon (USA), where study participants live and work at an elevation of 1200–1500 m above sea level.

Consumables

The active consumable product BiovaFlex[®] (450 mg/day) and placebo were provided by Biova LLC (Johnston, IA, USA). The placebo capsules contained microcrystalline

cellulose and were matched for appearance to the active capsules. The study participants were instructed to take one capsule in the morning. Adherence to the study protocol was evaluated at each visit by counting of returned capsules, interview with the study coordinator, and review of diary.

ROM using digital inclinometry

The evaluation of ROM was conducted in a detailed manner using the J-Tech Tracker Freedom dual digital inclinometry (J-Tech Medical, Midvale, UT, USA), where not only a person’s major area of discomfort was evaluated but also the entire vertical weight-bearing axis of the body was studied, from the neck to the knees. In addition, shoulder ROM was also evaluated. The rationale behind this detailed assessment is that often a person’s primary complaint (e.g., right hip) would lead to a compensated posture and compensated ROM of other anatomical areas as the person strived to put less pressure on a painful area, as previously described in studies for natural products.^{13–15}

Questionnaires on activities of daily living

At each visit, difficulties pertaining to physical functioning were evaluated using a set of 12 questions pertaining to daily activities and scored using unmarked 100-mm visual analog scales (VAS).

Pain assessment

The pain assessments at each 4-week visit involved the scoring of pain levels in different areas of the body (neck, shoulders, upper and lower back, hips, knees) when at rest and when physically active, where the scores were measured using unmarked 100-mm VAS. In addition, the study participants also answered a similar pain questionnaire daily, during both of the 4-week consumption phases of the 12-week crossover study.

Statistical analysis

The number of subjects was determined by power calculations based on data from a preliminary open-label pilot study, and this study was 90% powered to detect a 10% change. Statistical significance of changes from baseline to later assessments was evaluated by between-treatment analysis using the two-tailed independent *t*-test. Within-subject analysis was performed using the two-tailed paired *t*-test. Statistical significance was indicated if *P* < .05. Subgroup analysis was performed for the group receiving placebo before WSEM, the subgroup receiving WSEM before placebo, and the two subgroups enrolled at different times of the year.

RESULTS

Study demographics and compliance

The gender, age, and body mass index (BMI) were evenly distributed between the group receiving the active test product WSEM during the first 4-week consumption period (placebo during the second 4-week consumption period) and the group that received the products in reverse order (Table 1). The BMI

TABLE 2. COMPLIANCE WITH RESPECT TO CONSUMPTION OF TEST PRODUCTS IN THE CROSSOVER STUDY

	Average compliance (%)	Range (%)
Compliance during weeks 1–4	98.40	86–100
Compliance during weeks 9–12	97.81	89–100
Compliance during WSEM consumption	98.32	91–100
Compliance during placebo consumption	97.89	86–100
Compliance during entire study	98.10	88–100

Study participants were randomized to either consume WSEM during weeks 1–4 and placebo during weeks 9–12 or consume products in the reverse order.

range did not exceed 35 kg/m², and the average BMI was below 30 kg/m² for women and between 30 and 31 kg/m² for men. The adherence to study protocol and compliance was good and slightly higher during the consumption of WSEM. Mean compliance with respect to product consumption was at or higher than 86% throughout the study (Table 2).

Range of motion

Results from the ROM evaluations showed significant between-treatment improvements in ROM for the cervical lateral motion as well as for the right knee, after study participants consumed WSEM, compared to the same people consuming placebo (Fig. 1). Using within-subject statistical analysis, highly significant improvements in ROM were seen for all three ROM measurements of the neck as well as for the dominant shoulder.

Improved ability to perform daily activities

The level of difficulties of physical functioning associated with performing daily activities was scored at each visit




FIG. 1. Range of motion (ROM) evaluation. The average % increase in ROM is shown for the changes during consumption of WSEM (black bars) and placebo (gray bars). The data graph shows the average ROM change ± SEM. Statistical significance using between-treatment analysis is indicated by hash marks (#*P* < .05), and statistical significance using within-subject analysis is shown by asterisks (**P* < .1, **P* < .05, ***P* < .01). Abd, abduction; Add, adduction; F/E, flexion/extension; WSEM, water-soluble egg membrane.




FIG. 2. Difficulties performing 12 daily activities requiring complex joint motions are shown for changes in scores, occurring during consumption of WSEM (black bars) versus consumption of placebo (gray bars). The graph shows the group average change \pm SEM. There was no statistical significance using between-treatment analysis. Statistical significance using within-subject analysis is shown by asterisks (* $P < .1$, * $P < .05$, ** $P < .01$).

during the study (Fig. 2). The level of difficulty for each task was scored at the beginning and end of each 4-week consumption period, separated by the 4-week washout period. After consuming WSEM, subjects reported less difficulties in performing daily activities. There was no statistical significance using between-treatment analysis. Statistical significance using within-subject analysis showed significant improvements for a number of complex tasks associated with daily living.

Increased level of physical activity

At each visit, study participants were asked to score their level of physical activity over the past 4 weeks. These self-reported physical activity levels were significantly higher during the 4 weeks where participants were consuming WSEM than when the same participants were consuming placebo ($P < .05$) (Fig.

3A). In parallel, an increase in physical energy levels was reported, but did not reach statistical significance (Fig. 3B).

Pain reduction

Study participants were required to score pain levels for various anatomical areas on a daily basis. The results showed no significant pain reduction across the whole study population (one subgroup studied during the winter and another during spring) nor did it reach significance for the subgroup (eight people) studied during the spring. However, the data from the subgroup that were enrolled in the colder winter months showed pain reduction in the upper and lower back during WSEM consumption, compared to the scores during placebo consumption (Fig. 4). There was no significant difference in pain scores for the upper or lower back at the beginning of each 4-week consumption period.




FIG. 3. Change in levels of physical activity (A) and physical energy (B). The average score for physical activity levels for the past 4 weeks is shown as the group average \pm SEM for the scores collected after study participants consumed WSEM versus placebo. Self-reported physical activity levels were significantly higher during the 4 weeks where participants were consuming WSEM than when the same participants were consuming placebo (* $P < .05$). Self-reported physical energy levels also increased during WSEM consumption, but did not reach significance.




FIG. 4. Upper and lower back pain scores at rest (A, C) and when physically active (B, D) are shown for the subgroup ($N=13$) that participated in the crossover study during the winter season (November to February). The average scores for the first 5 days, first week, second week, third week, and fourth week are shown as the group average \pm SEM. There were no statistically significant differences between the baseline pain levels for any of the four scores. The reduction in lower back pain at rest was significantly lower after 5 days of WSEM consumption compared to placebo consumption ($*P < .05$), remaining significant between the treatments for weeks 1 and 2, and a statistical trend for weeks 3 and 4 ($(*)P < .071$). The reduction in lower back pain scores when physically active was significantly lower after 5 days of WSEM consumption compared to placebo consumption ($*P < .05$), remaining significant between the treatments throughout the remainder of the study.

Using between-treatment analysis of the changes in pain scores, a 43% reduction in upper back pain when at rest was seen after 5 days on WSEM, in contrast to 23% reduction for placebo. Upper back pain when physically active improved 33% on WSEM, in contrast to 15% for placebo. The 53% reduction in lower back pain when at rest after 5 days of WSEM consumption was significant when compared to placebo consumption ($P < .05$) and remained significantly lower than placebo scores for weeks 1 and 2 ($P < .05$) and remained lower than placebo throughout the 4-week phases ($P < .071$). The 49% reduction in lower back pain when physically active, compared to 23% reduction on placebo, after 5 days consumption was significant ($P < .05$), and the lower pain scores remained significant between the treatments throughout the remainder of the study.

Also on a daily basis, study participants were required to score pain levels for their identified area of primary pain at rest and when physically active. Reduced pain scores for primary pain when physically active were seen both when study participants consumed the active product and when

consuming placebo. The pain reduction during WSEM consumption reached between-treatment statistical significance in the subgroup that consumed WSEM first, whereas it was not significant in the subgroup that consumed placebo first. This suggests that subjects who consumed the active product during the initial 4-week study phase recognized a lack of similar effect when subsequently consuming the inactive placebo. This was verified by feedback from study participants. Due to the crossover design, all study participants experienced both WSEM and placebo. Eight study participants volunteered information at study visits that they experienced a positive effect when consuming WSEM, not matched by the placebo, even though the study was conducted in a double-blind manner where study participants were never told when they were receiving WSEM or placebo.

DISCUSSION

Joint mobility determines our ability to function, and maintaining good joint function and, thus, reducing sedentary behavior is a major factor in protecting our quality of

life as we age.¹⁶ In addition to age-related decline in joint function, many factors associated with diet and lifestyle contribute to reduction of joint mobility.¹⁷ Physical activity in midlife is associated with mobility limitations in old age, where maintaining leisure activities has a protective effect by supporting joint mobility in old age.¹⁸ Decreased joint ROM is associated with compensatory strategies.¹⁹ In addition, obesity adds biomechanical stress on weight-bearing joints, contributing to postural dysfunction, abnormal gait, and increased stiffness along the upper and lower back, all contributing to chronic pain and further loss of physical functionality.²⁰ Nondisease-related factors contributing to a decline in joint function and mobility include occupational stress,²¹ where additional factors affecting musculoskeletal mobility include mental stress-related muscular tension,²² which over time can contribute to chronic reduction of mobility, typically of the neck and back.

Chronic pain associated with physical limitations prompts the use of over-the-counter pain medication. Consumable natural products for improving joint function include the structural support provided by consuming compounds such as glucosamine, collagen, hyaluronan, and similar natural compounds known to help improve joint function.^{13–15,23–27} Additional consumables include polyphenol-rich natural products, known to provide both antioxidant protection and anti-inflammatory effects.^{28,29}

To study the impact of consumption of WSEM, this crossover study was designed to include people experiencing chronic pain in shoulders, hips, or knees, with associated reduced physical functioning for at least 6 months. The intent was not to study a diseased population such as subjects with osteoarthritis, but rather to evaluate improvements in a typical middle-aged population experiencing some joint discomfort. The study aimed at gathering data regarding improvements in joint function and mobility, as well as physical functioning associated with consumption of WSEM. It was important to use a crossover study design to evaluate any improvements during WSEM consumption in light of changes occurring in the same set of people when consuming placebo.

The consumption of WSEM was associated with generally improved ROM for spinal motion, including the neck, upper back, and lower back, as well as major joints such as the dominant shoulder and knee. The observation that improvements were of a general nature, and not limited to each person's primary pain area defined at the time of screening, suggests underlying support of joint and muscle functions. The significant improvement of neck motion was unexpected, since these areas were not defined as primary complaints at screening. The improved ROM for the dominant shoulder suggests improved muscular function and relief of tension, such as could be speculated to be associated with a mild chronic inflammatory condition. A previous placebo-controlled parallel-arm study on WSEM consumption in subjects with symptoms of osteoarthritis showed a significant reduction in CRP during WSEM consumption, in contrast to placebo (manuscript in preparation). Further studies on WSEM should include testing of free radical stress

as well as cytokines involved in regulating inflammation and supporting regenerative functions.

In addition to collecting data on joint mobility and physical functioning, an important ancillary observation was a significant increase in self-reported physical activity levels. Physical activity is important in healthy aging,^{27,28} and studies have shown that even moderate increases in physical activity levels can contribute significantly to prevention of age-related dementia through prevention of hippocampal atrophy.²⁹

The study also involved daily scoring of pain levels when at rest and when physically active. This data did not provide a significant pain reduction when analyzed across the two sets of subjects enrolled across different seasons, each having an associated weather profile. Subgroup analysis was performed on each set of study participants and showed that the subgroup enrolled in the study during the winter months, with a fairly stable weather pattern in the given geographical area, showed a rapid and sustained pain relief, which reached statistical significance for the lower back. Feedback from the study participants suggests that the pain relief happened as a result of WSEM consumption and subsequently facilitated an increase in physical activity. A future study should include systematic daily tracking of physical activity as well to help conclude the cause/effect relation and verify this correlation.

In conclusion, the data presented here showed improved mobility and ability to conduct daily activities when consuming WSEM. This study is important because the study population was not diagnosed with a joint disease, such as, for example, osteoarthritis, and the improvements were broad and independent of a person's identified major joint problem(s). Furthermore, the increase in physical energy and activity levels may potentially over time allow for reduction in body fat percentage and an increase in relative percentage of lean body mass. The parallel observations for increased physical energy levels suggest that consuming WSEM may hold promise as a natural support of maintaining quality of life in the aging human. Further studies are warranted in different study populations, such as geriatrics, athletes, and people recovering from trauma to joints and muscles.

ACKNOWLEDGMENTS

The study was conducted at NIS Labs, an independent contract research laboratory specializing in natural products research. The study was sponsored by Biova LLC (Johnston, IA, USA), the manufacturer of hydrolyzed WSEM.

AUTHOR DISCLOSURE STATEMENT

All authors are associated with NIS Labs and have no competing financial interest in the subject matter.

REFERENCES

1. Ahlborn G, Sheldon BW: Identifying the components in eggshell membrane responsible for reducing the heat resistance of bacterial pathogens. *J Food Prot* 2006;69:729–738.

2. Abdel Mageed AM, Isobe N, Yoshimura Y: Immunolocalization of avian beta-defensins in the hen oviduct and their changes in the uterus during egg formation. *Reproduction* 2009;138:971–978.
3. Yang JY, Chuang SS, Yang WG, Tsay PK: Egg membrane as a new biological dressing in split-thickness skin graft donor sites: A preliminary clinical evaluation. *Chang Gung Med J* 2003;26:153–159.
4. Maeda K, Sasaki Y: An experience of hen-egg membrane as a biological dressing. *Burns* 1981;8:313–316.
5. Farjah GH, Heshmatian B, Karimipour M, Saben A: Using eggshell membrane as nerve guide channels in peripheral nerve regeneration. *Iran J Basic Med Sci* 2013;16:901–905.
6. Chai Z, Li Y, Liu F, Du B, Jiao T, Zhang C, Leng X: Outer eggshell membrane as delivery vehicle for polysaccharide/protein microcapsules incorporated with vitamin E. *J Agric Food Chem* 2013;61:589–595.
7. Mogosanu GD, Grumezescu AM: Natural and synthetic polymers for wounds and burns dressing. *Int J Pharm* 2014;463:127–136.
8. Ruff KJ, DeVore DP, Leu MD, Robinson MA: Eggshell membrane: A possible new natural therapeutic for joint and connective tissue disorders. Results from two open-label human clinical studies. *Clin Interv Aging* 2009;4:235–240.
9. Ruff KJ, Winkler A, Jackson RW, DeVore DP, Ritz BW: Eggshell membrane in the treatment of pain and stiffness from osteoarthritis of the knee: A randomized, multicenter, double-blind, placebo-controlled clinical study. *Clin Rheumatol* 2009;28:907–914.
10. Ruff KJ, Endres JR, Clewell AE, Szabo JR, Schauss AG: Safety evaluation of a natural eggshell membrane-derived product. *Food Chem Toxicol* 2012;50:604–611.
11. Benson KF, Ruff KJ, Jensen GS: Effects of natural eggshell membrane (NEM) on cytokine production in cultures of peripheral blood mononuclear cells: Increased suppression of tumor necrosis factor- α levels after in vitro digestion. *J Med Food* 2012;5:360–368.
12. Ohto-Fujita E, Konno T, Shimizu M, Ishihara K, Sugitate T, Miyake J, Yoshimura K, Taniwaki K, Sakurai T, Hasebe Y, Atomi Y: Hydrolyzed eggshell membrane immobilized on phosphorylcholine polymer supplies extracellular matrix environment for human dermal fibroblasts. *Cell Tissue Res* 2011;345:177–190.
13. Jensen GS, Ager DM, Redman KA, Mitzner MA, Benson KF, Schauss AG: Pain reduction and improvement in range of motion after daily consumption of an açai (*Euterpe oleracea* Mart.) pulp-fortified polyphenolic-rich fruit and berry juice blend. *J Med Food* 2011;14:702–711.
14. Benson KF, Ager DM, Landes B, Aruoma OI, Jensen GS: Improvement of joint range of motion (ROM) and reduction of chronic pain after consumption of an ergothioneine-containing nutritional supplement. *Prev Med* 2012;54 Suppl:S83–S89.
15. Jensen GS, Attridge VL, Benson KF, Beaman JL, Carter SG, Ager D: Consumption of dried apple peel powder increases joint function and range of motion. *J Med Food* 2014;17:1204–1213.
16. van der Berg JD, Bosma H, Caserotti P, Eiriksdottir G, Arnardottir NY, Martin KR, Brychta RJ, Chen KY, Sveinsson T, Johannsson E, Launer LJ, Gudnason V, Jonsson PV, Stehouwer CD, Harris TB, Koster A: Midlife determinants associated with sedentary behavior in old age. *Med Sci Sports Exerc* 2014;46:1359–1365.
17. Messier SP, Mihalko SL, Legault C, Miller GD, Nicklas BJ, DeVita P, Beavers DP, Hunter DJ, Lyles MF, Eckstein F, Williamson JD, Carr JJ, Guermazi A, Loeser RF: Effects of intensive diet and exercise on knee joint loads, inflammation, and clinical outcomes among overweight and obese adults with knee osteoarthritis: The IDEA randomized clinical trial. *JAMA* 2013;310:1263–1273.
18. Hinrichs T, von Bonsdorff MB, Törmäkangas T, von Bonsdorff ME, Kulmala J, Seitsamo J, Nygård CH, Ilmarinen J, Rantanen T: Inverse effects of midlife occupational and leisure time physical activity on mobility limitation in old age—A 28-year prospective follow-up study. *J Am Geriatr Soc* 2014;62:812–820.
19. Ko SU, Simonsick EM, Ferrucci L: Gait energetic efficiency in older adults with and without knee pain: Results from the Baltimore Longitudinal Study of Aging. *Age (Dordr)* 2015;37:9754.
20. Vincent HK, Adams MC, Vincent KR, Hurley RW: Musculoskeletal pain, fear avoidance behaviors, and functional decline in obesity: Potential interventions to manage pain and maintain function. *Reg Anesth Pain Med* 2013;38:481–491.
21. Jay K, Brandt M, Sundstrup E, Schraefel M, Jakobsen MD, Sjøgaard G, Andersen LL: Effect of individually tailored biopsychosocial workplace interventions on chronic musculoskeletal pain, stress and work ability among laboratory technicians: Randomized controlled trial protocol. *BMC Musculoskelet Disord* 2014;15:444.
22. Bonzini M, Bertu' L, Veronesi G, Conti M, Coggon D, Ferrario MM: Is musculoskeletal pain a consequence or a cause of occupational stress? A longitudinal study. *Int Arch Occup Environ Health* 2015;88:607–612.
23. Crowley DC, Lau FC, Sharma P, Evans M, Guthrie N, Bagchi M, Bagchi D, Dey DK, Raychaudhuri SP: Safety and efficacy of undenatured type II collagen in the treatment of osteoarthritis of the knee: A clinical trial. *Int J Med Sci* 2009;6:312–321.
24. Lugo JP, Saiyed ZM, Lau FC, Molina JP, Pakdaman MN, Shami AN, Udani JK: Undenatured type II collagen (UC-II®) for joint support: A randomized, double-blind, placebo-controlled study in healthy volunteers. *J Int Soc Sports Nutr* 2013;10:48.
25. Balogh L, Polyak A, Mathe D, Kiraly R, Thuroczy J, Terez M, Janoki G, Ting Y, Bucci LR, Schauss AG: Absorption, uptake and tissue affinity of high-molecular-weight hyaluronan after oral administration in rats and dogs. *J Agric Food Chem* 2008;56:10582–10593.
26. Jensen GS, Attridge VL, Lenninger MR, Benson KF: Oral intake of a liquid high-molecular-weight hyaluronan associated with relief of chronic pain and reduced use of pain medication: Results of a randomized, placebo-controlled double-blind pilot study. *J Med Food* 2015;18:95–101.
27. Rahe J, Petrelli A, Kaesberg S, Fink GR, Kessler J, Kalbe E: Effects of cognitive training with additional physical activity compared to pure cognitive training in healthy older adults. *Clin Interv Aging* 2015;10:297–310.
28. Robitaille A, Muniz G, Lindwall M, Piccinin AM, Hoffman L, Johannsson B, Hofer SM: Physical activity and cognitive functioning in the oldest old: Within- and between-person cognitive activity and psychosocial mediators. *Eur J Ageing* 2014;11:333–347.
29. Varma VR, Chuang Y, Harris GC, Tan EJ, Carlson MC: Low-intensity daily walking activity is associated with hippocampal volume in older adults. *Hippocampus* 2015;25:605–615.